Quantum Surgical, a company specializing in robotic-assisted cancer treatment, announced the acquisition of NeuWave Medical, a company Johnson & Johnson bought in 2016.
Quantum and NeuWave will operate as subsidiaries of Precision IO Group Inc., the newly created parent company.
The group’s ambition is to become a leader in the interventional radiology industry, with a strong focus on precision and remote procedures.
Quantum has developed the Epione robotic platform for treating early-stage tumors. Epione assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to treat the tumor. It's CE marked for abdominal, chest, and musculoskeletal structures indications, and FDA cleared for the abdominal ablation indication.
NeuWave offers microwave ablation technology that provides a physician-friendly workflow during percutaneous ablations.
Medtech leader Kurt Azarbarzin has been appointed to lead Precision IO. He is the former Founder and CEO of SurgiQuest, Inc., a medical device company focused on advancing minimally invasive surgery, and also served as CEO of EndoQuest Robotics and Verb Surgical, a robotic joint venture between Johnson & Johnson and Google.
“I am excited and honored to join Precision IO Group Inc. as CEO,” said Azarbarzin in a statement. “Quantum Surgical and NeuWave Medical, Inc. are highly complementary and share an incredible vision for the future. I have met both teams and am impressed by the pride and passion they bring to their work to improve patient care. I believe that their technologies, both independently and combined, have the potential to position us as leaders of the industry, and to transform cancer care on a global scale. Drawing on my 40 years of experience in minimally invasive surgery, I am convinced that AI, robotics and enabling remote interventions are game-changers for cancer care and interventional radiology.
